International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: head and neckLate toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems
Introduction
Most oropharyngeal carcinomas are locally advanced at presentation 1, 2. Thus, patients are often treated using radiotherapy (RT), but the results are poor. In 1994, the French Head and Neck Oncology and Radiotherapy Group (GORTEC) initiated a randomized, Phase III, multicenter clinical trial to evaluate prospectively the benefit of a concomitant radiochemotherapy schedule vs. RT alone for advanced-stage oropharynx carcinoma. The combined modality treatment led to increased 3- and 5-year overall survival rates and 3- and 5-year locoregional control rates 3, 4. However, normal tissue radiation late effects remain a major problem for long-term surviving patients. In head-and-neck cancer, radiation late toxicity was usually assessed using the National Cancer Institute (NCI) or the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) scale (5). Then, it was proposed to replace all late toxicity scales with the Late Effect Normal Tissue Task Force (LENT)/subjective, objective, management, analytic (SOMA) scale resulting from an international collaboration between the EORTC and RTOG subcommittees to standardized the toxic effects criteria (6). The purpose of this study was to assess prospectively the late toxic effects observed when patients are treated with RT alone or RT and concomitant chemotherapy. This analysis was performed using the three different toxicity scales (LENT/SOMA, NCI-Common Toxicity Criteria [CTC], and RTOG/EORTC) simultaneously. The accuracy and concordance of these scales were evaluated.
Section snippets
Study design
Patients were included in the study if all the following criteria were met: invasive squamous cell carcinoma of the oropharynx (Stage III or IV, without evidence of distant metastases), <75 years old, and Karnofsky performance score of ≥60. Patients were excluded if they had previously undergone treatment for this disease or any other cancer (except basal cell carcinoma of the skin) or if they had synchronous primary lesions. Other criteria for inclusion included a neutrophil count >1500
Toxicity scale comparison
In the combined-modality arm (Arm B), 27 patients were alive at 5 years; in the RT-alone arm (Arm A) 17 were alive. Thus, 44 questionnaires were studied to compare the toxicity scales with each other.
Transposability of patients’ symptoms to toxicity items
Ninety Grade 1–4 toxic events were assessed using the RTOG/EORTC combined with the LENT/SOMA scale. Seventy-four percent of the events were found using only the RTOG/EORTC scale and 80% were found using only the LENT/SOMA scale (p = not significant).
Eighty-four Grade 1–4 toxic events were assessed
Discussion
In this prospective study, we compared three toxicity scales to assess prospectively the late toxicity rate of a concomitant chemoradiation schedule vs. RT alone for locally advanced oropharynx carcinoma. We first found that the transposability of patients’ symptoms was significantly higher using the LENT/SOMA or RTOG/EORTC scaling systems than using the NCI-CTC system. The LENT-SOMA had the best transposability rate for all but one organ damage (salivary glands). For this toxicity, the
Conclusion
Concomitant chemoradiation for locally advanced oropharynx carcinoma increased the overall survival rate and locoregional control rate but did not increase severe complications. The late toxicity assessment of a treatment may depend on the toxicity scale used, confirming the necessity of using a common late toxicity scale in clinical trials.
Acknowledgements
Other authors included the following: Dr. Alavena (Avignon), Dr. Ardiet (Lyon Sud), Dr. Auregan (Bourges), Dr. Cailleux (Tours), Dr. Chaib-Rassou (Metz), Dr. Delpon (Le Mans), Dr. Desprez (Vannes), Dr. Favre (Orléans), Dr. Hardiet (Lyon), Dr. Maillard (Angers), Dr. Oudinot (Le Havre), Dr. Raoul (St. Grégoire), and Dr. Gesta (Niort).
References (9)
- et al.
Valeur pronostique du nombre de ganglions envahis après curage cervical pour carcinoma de l’oropharynx et de la cavité buccale
Cancer Radiother
(2001) - et al.
System d’évaluation des effets tardifs des radiations ionisantes sur les tissus normauxl’échelle SOMA-LENT
Cancer Radiother
(1997) - et al.
TID radiotherapy with or without alternating chemotherapy in patients with a locally advanced squamous cell carcinoma of the head and neckAn analysis of late toxicity
Cancer Radiother
(2001) - et al.
Late radiation effects to the rectum and bladder in gynecologic cancer patientsThe comparison of LENT/SOMA and RTOG/EORTC late effects scoring systems
Int J Radiat Oncol Biol Phys
(2001)